

## Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression

### Supplementary Materials

**Supplementary Table 1: Details of the samples included in the 5-hmc and/or RT-qPCR analyses**

Name	Subtype	% Tumor cells	PVL <sup>a</sup>	5-hmc	TET2 <sup>b</sup>	TET3 <sup>b</sup>	Survival <sup>c</sup>
ATLL 01	Acute	85%	27	ND	1,86	4,38	79.6 (1)
ATLL 05	Acute	85%	104	0,05	0,798	0,965	1.7 (1)
ATLL 07	Acute	> 80%	83	0,35	0,845	0,42	8.8 (1)
ATLL 10	Acute	95%	175	0,19	0,6885	0,6295	6.9 (1)
ATLL 14	Acute	85%	265	0,17	0,74	0,61	11.8 (1)
ATLL 25	Acute	95%	64	0,48	0,875	1,085	2.7 (1)
ATLL 28	Acute	96%	24	ND	1,825	0,5	4.6 (1)
ATLL 30	Acute	100%	290	ND	1,155	1,055	7.7 (1)
ATLL 36	Acute	95%	172	0,53	1,985	2,185	5.9 (1)
ATLL 38	Acute	90%	200	ND	1,01	2,87	5.6 (0)
ATLL 57	Acute	85%	67	0,14	0,935	1,19	24.2 (1)
ATLL 59	Acute	>60%	164	0,17	1,7	0,45	3.2 (1)
ATLL 61	Acute	90%	97	0,28	0,76	0,29	4.3 (1)
ATLL 62	Acute	90%	99	0,23	0,99	1.44	2.5 (1)
ATLL 66	Acute	97%	449	ND	0,87	0,52	1.3 (1)
ATLL 71	Acute	95%	556	ND	0,48	0,48	4.5 (1)
ATLL 74	Acute	98%	ND	0,28	0,6	0,65	0.5 (1)
ATLL 75	Acute	70%	168	0,08	1.17	2.02	5.3 (1)
ATLL 80	Acute	73%	ND	ND	0,5	0,42	21 (1)
ATLL 82	Acute	71%	>200%	ND	0,41	0,15	9.8 (1)
ATLL 88	Acute	98%	370	0,32	0,59	0,42	8.6 (1)
ATLL 02	Chronic	85%	355	0,27	1,69	1,48	28 (1)
ATLL 08	Chronic	77%	79	0,32	2,355	0,855	87 (0)
ATLL 11	Chronic	80%	33	0,62	3,25	3,46	84 (0)
ATLL 22	Chronic	>70%	110	0,62	2,5	1	63 (1)
ATLL 23	Chronic	80%	81	0,6	1,795	1,76	28.7 (1)
ATLL 37	Chronic	75%	80	0,44	1,545	1,515	36 (1)
ATLL 56	Chronic	70%	99	0,56	1,66	1,99	46 (0)
ATLL 91	Chronic	83%	234	0,33	0,7	0,97	10.2 (0)

<sup>a</sup>Proviral load is expressed as number of proviral copies per 100 PBMC.

<sup>b</sup>Mean Normalized Relative Quantity (NRQ) were calculated from two independent experiments performed in triplicates.

<sup>c</sup>Survival is expressed in months. Number 1 or 0 indicates death or survival of the patients, respectively.

ND: not determined.

**Supplementary Table 2: Comparison of TET, TET2 or TET3 mRNA expression in PBMC from carriers or ATLL patients**

	<b>2-<math>\Delta</math>Cp Tet1 /HPRT</b>	<b>2-<math>\Delta</math>Cp Tet2 /HPRT</b>	<b>2-<math>\Delta</math>Cp Tet3 /HPRT</b>
<b>Carriers HC5</b>	8,62E-04	3,67E-01	1,71E-01
<b>ATLL 37</b>	1,16E-03	5,30E-01	1,82E-01
<b>ATLL 61</b>	1,12E-03	2,32E-01	5,98E-02
<b>Tonsil B cells</b>	3,91E-02	ND	ND

ND: not determined.